VaxGen, Inc. To Hold Conference Call And Webcast On Wednesday, Nov. 2

BRISBANE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- WHAT: VaxGen will hold a conference call and webcast Wednesday, November 2, 2005 to review today’s announcement regarding the anticipated timing for filing of the company’s financial statements and its anthrax vaccine program. WHEN: Wednesday, November 2, 2005 10:00am Eastern Time WHERE: Live Call: Domestic: 800-374-0113 International: 706-758-9607 No passcode required. Replay: Domestic: 800-642-1687 International: 706-645-9291 Passcode: 2128052 WEBCAST: To access the webcast, go to Events/Webcasts in the Investor Relations section of VaxGen’s web site at www.vaxgen.com/invest and click on “Update Regarding Financial Statements and Anthrax Vaccine Program.” The webcast will be available for replay for 72 hours. About VaxGen

VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax, smallpox and Meningitis B. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 22% of Celltrion, Inc., a South Korean operation established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at: http://www.vaxgen.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk,photodesk@prnewswire.comVaxGen, Inc.

CONTACT: Pat Beaupre Becker of VaxGen, +1-650-624-1041

MORE ON THIS TOPIC